Research programme: pain therapeutics - AstraZeneca

Drug Profile

Research programme: pain therapeutics - AstraZeneca

Alternative Names: AZ 09; AZ 11760788; AZ 12048189; AZ 12099548; AZ 1297442; AZ 599; AZD 7903; AZD 9335

Latest Information Update: 06 Sep 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AstraZeneca
  • Class 3-ring heterocyclic compounds; Indoles; Isoxazoles; Pyridines; Sulfonamides
  • Mechanism of Action Bradykinin B2 receptor antagonists; Cannabinoid receptor CB1 agonists; Nav1.7-voltage-gated-sodium-channel-inhibitors; Sodium channel antagonists; TRPV1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Inflammatory pain; Neuropathic pain
  • Discontinued Gastro-oesophageal reflux

Most Recent Events

  • 31 Aug 2012 Pharmacodynamics data from a Preclinical trial in Neuropathic pain presented at the 14th World Congress on Pain (WCP-2012)
  • 31 May 2012 Preclinical trials in Neuropathic pain in Canada (IV)
  • 02 Sep 2011 Preclinical development is ongoing in Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top